Seeking Alpha

Acadia (ACAD) +6.4% after saying that its Pimavanserin performed well in a Phase III trial,...

Acadia (ACAD) +6.4% after saying that its Pimavanserin performed well in a Phase III trial, showing a "robust and consistent efficacy...across a wide array of study measures" and confirming previous "positive top-line results." Twice as many patients treated with pimavanserin were rated as "very much improved or much improved" vs those given a placebo. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs